Biotech

Index is splitting its life sciences and technology arms into two separate VC firms and launching Medicxi Ventures with new €210 million fund

New accelerator will initially work with the tech transfer team of three research institutes to uncover promising new ideas

It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

Oslo-based anticancer company Algeta has closed a series A financing round totaling €23 million.

A new life-science fund said it raised €240.3 million – and promptly announced its first two investments.